Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-D MatrixDMTRF 56 EV-to-EBIT is 9.14 as of Jul. 19, 2026. GuruFocus rates DMTRF with a GF Score™ of 56/100 and a GF Value™ of $2.17 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 465 Medical Devices & Instruments companies, 3-D Matrix ranks better than 79.14% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
3-D Matrix's Enterprise Value for the quarter that ended in Jan. 2026 was $275.17 Mil.
3-D Matrix's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3-D Matrix EV-to-EBIT Related Terms
3-D Matrix EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for 3-D Matrix's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, 3-D Matrix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3-D Matrix EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 3-D Matrix's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where 3-D Matrix's EV-to-EBIT falls into.
3-D Matrix's current Enterprise Value is $247.77 Mil.
3-D Matrix's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3-D Matrix (DMTRF) has a EV-to-EBIT of 9.14 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on 3-D Matrix and its competitors. According to the industry distribution chart, 3-D Matrix ranks #97 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 20.9%.
Is 3-D Matrix's EV-to-EBIT too high?
3-D Matrix's current EV-to-EBIT is 9.14. The Medical Devices & Instruments industry median EV-to-EBIT is 18.43. 3-D Matrix's value of 9.14 is 50.4% below this industry median. Based on the distribution chart, 3-D Matrix ranks #97 out of 465 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, 3-D Matrix has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3-D Matrix's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, 3-D Matrix ranks #97 out of 465 companies for EV-to-EBIT. This places 3-D Matrix in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.43. 3-D Matrix's value of 9.14 is 50.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.43, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3-D Matrix's current EV-to-EBIT of 9.14 is 50.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on 3-D Matrix and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3-D Matrix's current EV-to-EBIT is 9.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3-D Matrix stock overvalued right now?
Based on GuruFocus' analysis, 3-D Matrix (DMTRF) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.17, compared to a current price of $2.50 — trading 15.2% above its estimated fair value. The current EV-to-EBIT is 9.14 and 50.4% below the Medical Devices & Instruments industry median of 18.43. 3-D Matrix's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For 3-D Matrix (DMTRF), the current EV-to-EBIT is 9.14 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3-D Matrix (DMTRF) Overvalued in 2026?
Based on GuruFocus' analysis, 3-D Matrix stock appears to be overvalued.
The current stock price of $2.50 is trading 15.2% above its estimated GF Value™ of $2.17.
GuruFocus considers 3-D Matrix to be Modestly Overvalued.
Key valuation signals for DMTRF:
EV-to-EBIT: 9.14
GF Value™: $2.17 vs. price of $2.50 (15.2% above fair value)
Industry Position: 50.4% below the Medical Devices & Instruments median (#97 of 465)
No single metric tells the full story. See the DMTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3-D Matrix Ltd is engaged in the research, development, manufacture, and sale of medical devices based on the self-assembling peptide technology. Its products include PuraMatrix, High Concentration PuraMatrix, Modified Peptide and GMP Grade PuraMatrix.
56GF Score
Get the complete analysis for DMTRF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMTRF has been successfully added to your 
